Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
GOOD OR BAD BUGS, FRIEND OR FOES: UNRAVELING DIFFERENCES BETWEEN MUTUALISM AND PATHOGENICITY IN BURKHOLDERIA SPECIES (GOOD OR BAD BUGS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-09-01
End date: 2023-08-31
Duration (months): 24.0
Total project cost (EUR): 191149.44
EU funding (EUR): 191149.44
Participants: 1
Project status: SIGNED

"What better microbial challenge to unite agricultural and medical microbiologists than a microoorganism that reduces an onion to a macerated pulp, protects crops from diseases, devastates the health and social life of cystic fibrosis patients, and not only is resistant to the most famous antibiotic, penicillin, but can use it as a nutrient!". The genus Burkholderia accommodates around 120 species that colonize a wide range of ecological niches and interact with hosts in different ways such as mutualism, commensalism or pathogenicity. Opportunistic pathogens like B. cenocepacia cause severe infections in cystic fibrosis and immunocompromised patients, and mutualists such as B. phytofirmans are beneficial to plants. Although very promising for agriculture, the use of the latter is severely restrained due to the potential threat that a few opportunistic pathogenic strains pose to human health. In the last years, a lot of effort has been invested into discriminating between the beneficial and the pathogenic strains. However, these studies have been unsuccessful so far and novel approaches are needed to better understand the potential risks/benefits associated to Burkholderia species before these can keep being used in agriculture. Friends or foes? The GOOD OR BAD BUGS project aims to unravel the dissimilarities between the beneficial (the good) and the pathogenic (the bad) Burkholderia species. We hypothesize that differences in the genomes of the Burkholderia species allow them to colonize and interact with their host differently, leading to mutualism, commensalism or pathogenicity. In this project we will employ a cutting-edge high-throughput genetic screening method known as transposon-sequencing to study host colonization by members of the genus Burkholderia. This promising methodology will help to identify genes that provide a fitness in a particular environment. The outcome of the project will be of interest both at the agriculture and the medicine levels.

Keywords: burkholderia cenocepacia,burkholderia thailandensis,burkholderia phytofirmans,host microbe interactions,host colonization,plant growth promotion,pathogenicity,mutualism,transposon sequencing
Optimal design and control of cruise ship energy systems (ODes aCCES)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Switzerland
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-01-03
End date: 2019-01-02
Duration (months): 24.0
Total project cost (EUR): 175419.6
EU funding (EUR): 175419.6
Participants: 1
Project status: CLOSED

This project aims at improving the energy efficiency of cruise ship energy systems by applying principles of process integration while taking into account the issues related to system optimal control. In particular, the project aims at providing: - Detailed information on the main challenges and requirements for the application of the concept of simultaneous optimisation of design and control to ship energy systems design. - An estimation of the energy savings potential related to the application of the aforementioned optimization concept to cruise ships. The project’s aim should be seen as part of broader efforts in reducing anthropogenic CO2 emissions and in reinforcing the competitive strength of the European cruise and shipbuilding industries, which have been facing, in recent years, an increasing number of challenges in terms of fluctuating fuel prices, stricter environmental regulations, and concerns about global warming. The project will also allow a significant development of the experienced researcher in advancing his career as an expert in energy systems engineering by providing him with competence in the fields of process integration and control systems engineering. The project will develop in three main phases. The first to phases will include the application of the process integration and the control system engineering perspectives separately, in order to reduce the complexity of the problem. The two aspects will be combined in the final part of the project. This procedure will be applied to a number of case studies in order to make sure that potential challenges to the application of the presented methodology to real cases will be identified, and to ensure the validity of the results.

Keywords: low carbon shipping
IgEPath - Contributions of IgE-antibodies and IgE effector cells to host defense against pathogenic bacteria (IgEPath)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Austria
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-08-03
End date: 2017-08-02
Duration (months): 24.0
Total project cost (EUR): 166156.8
EU funding (EUR): 166156.8
Participants: 1
Project status: CLOSED

In combination, Immunoglobulin E antibodies (IgEs) and IgE effector cells, most importantly mast cells (MCs) and basophils, are best known for their disease-causing roles in allergic conditions. MCs can also participate in innate host defense against pathogens and toxins. In contrast, physiologic functions of IgEs that benefit the host are still elusive. Dr. Philipp Starkl led a recent study reporting the critical role of IgEs and IgE effector cells in a beneficial type 2 immune response against bee venom in mice, supporting the idea that allergies represent defense mechanisms against toxins. Toxins that induce IgE development are also produced by various pathogenic bacteria. IgE production during bacterial infection has been considered detrimental since it is associated with the exacerbation of atopic diseases. This study investigates the hypothesis that toxin-specific IgEs can be important for acquired immunity against pathogenic bacteria by increasing the sensitivity, extent and specificity of the bactericidal MC response. The main objective of this study is to decipher the roles of IgEs and IgE effector cells in host defense against invasive secondary infections with antibiotic resistant pathogenic bacteria, which are a major health problem in Europe. The experimental approach facilitates knowledge transfer between the US and EU and complementarily combines the applicant’s expertise in type 2 immunity, IgEs and MCs (acquired in the US) and Prof. Sylvia Knapp’s competence in bacterial infections and involves in vivo mouse models of infection in transgenic mouse strains and MC in vitro models. The secondment in a pharmaceutical company will inspire collaboration and translation of results into vaccine development. This MSC fellowship will support the applicant’s career development by fostering acquisition of novel expertise in infectious diseases, collaboration with and reintegration into the European research community and connecting with the industrial sector.

Keywords: ige antibodies,mast cells,toxins,allergy,host defense,pathogenic bacteria
Enterprise Grade Lean AI platform (BrainMatter)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Netherlands
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-05-01
End date: 2019-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Artificial Intelligence (AI) appears to be the next big thing that will contribute immensely to businesses’ growth and change the rules of competition, as demonstrated by the growing AI for enterprise applications, a market expected to reach €5.8 billion by 2024. Current AI and ML models are trained via supervised learning, in which manually labeled data is fed into AI models such as regression algorithms. Labeling huge datasets, however, need a lot of human interaction, attention, and effort, which slows down productivity, is prone to errors and, more importantly, very costly. Our company, BrainCreators, is well paired to address this issue. We deliver innovative AI solutions and to date have accelerated >40 companies in their root cause analysis, language interpretation, predictive maintenance, and quality control related projects. Our innovation, BrainMatter, is a unique enterprise-grade lean AI platform that will offer businesses, and their data scientist teams, a fully customizable data processing solution, that streamlines the full AI lifecycle from the creation of high quality, large data sets to the training and deployment of AI models. It is applicable for a diverse range of data - image recognition, audio, text, video, time series, sensor data. Our innovation is customizable, self-learning, and in line with lean principles, improves accuracy with continuous model training. At the management level, BrainMatter will enable companies to save costs, speed up the labeling process, give control over the process with a customizable dashboard, and improve security through on-premise usage. At the implementation level, it will support data scientists and empower them to dedicate more time towards high-value-added tasks. After five years of exploitation, we expect BrainMatter to boost our revenues to €17.6 million (with an ROI above 3 euro per euro invested), creating 78 direct and over 2,000 indirect jobs in the process.

Keywords: artificial intelligence,machine learning,aiaas platform,data preparation,data labeling,data processing,data scientists,supervised learning,big data
Diversifying revenue in rural Africa through circular, sustainable and replicable bio-based solutions and business models (BIO4AFRICA)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive bio-based industries and supporting the development of a European bio-economy
Action type: Research and Innovation actions
Countries involved: Spain,Uganda,Ireland,Spain,Spain,Ireland,Côte d'Ivoire,Greece,France,France,Netherlands,Netherlands,United Kingdom,Ghana,Kenya,Senegal,Denmark
Call: Diversifying revenue in rural Africa through bio-based solutions (H2020-SFS-2020-2, 2020)
Start date: 2021-06-01
End date: 2025-05-31
Duration (months): 48.0
Total project cost (EUR): 8999693.75
EU funding (EUR): 8999693.75
Participants: 25
Project status: SIGNED

Africa will need to feed over 2 billion people by 2050 while coping with unprecedented demographic, socio-economic, environmental, climatic and health transitions. Meanwhile, undernourishment is still on the rise, affecting almost 20% of its population now. Under this light, ensuring Africa’s food security becomes imperative, with the bioeconomy posed to play a leading role to this end. It is against this backdrop that BIO4AFRICA sets off to support the deployment of the bioeconomy in rural Africa via the development of bio-based solutions and value chains with a circular approach to drive the cascading use of local resources and diversify the income of farmers. Our focus is on transferring simple, small-scale and robust bio-based technologies adapted to local biomass, needs and contexts (green biorefinery, pyrolysis, hydrothermal carbonisation, briquetting, pelletising, bio-composites and bioplastics production). In doing so we aim at empowering farmers to sustainably produce a variety of higher value bio-based products and energy (animal feed, fertiliser, pollutant absorbents, construction materials, packaging, solid fuel for cooking and catalysts for biogas production), significantly improving the environmental, economic and social performance of their forage agri-food systems. To this end, we have set up 4 pilot cases with over 8 testing sites in Uganda, Ghana, Senegal and Ivory Coast, offering more than 300 farmers and farmer groups of all sizes (incl. small dairy and lower-income farmers, women farmer groups and transhumant pastoralists among others) the opportunity to test them in real productive conditions. Along the way, our balanced mix of 13 African and 12 EU partners will engage in solid multi-actor collaboration with rural communities and government, co-developing novel sustainable value chains driven by circular business models and supporting deployment in other areas, all while safeguarding agronomic, environmental, social and economic sustainability.

Keywords: bio based technologies,circular business models,small scale biorefinery,high value feed,biochar,biomaterials,fertilizer,bioenergy,sustainable rural development,income diversification
Family Policy Measurement Tool: Advanced Methodologies for Understanding Inequalities in Family Policy (FAMPOT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Belgium
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-10-01
End date: 2022-09-30
Duration (months): 24.0
Total project cost (EUR): 178320.0
EU funding (EUR): 178320.0
Participants: 1
Project status: CLOSED

Family policies impact upon many aspects of people’s lives such as couples’ income dynamics, engagement in childcare activities or labour market participation. However, the degree to which these mechanisms vary between people with different socio-economic statuses is not well understood. Consequently, we don’t know who benefits from these policies and who is losing out on support. A policy measurement tool capable of recognising the family policy entitlements of each individual would provide an unprecedented insight into how well specific populations are protected against various social risks. Not only that, it would allow researchers to map the generosity of family policies across countries with greater accuracy and to test the effect of family policies on human behaviour with greater precision. Insufficient knowledge of the mechanisms through which policies influence people’s lives and the potentially differential effect of various family policies on people’s income and living conditions considerably limit our ability to provide effective policy recommendations that would lead to desirable outcomes. This MSCA Fellowship aims to create such a measurement tool and use it in the investigation of gender and socio-economic inequality in access to family policy support for families with young children (maternity, paternity, parental and childcare leave, child-related cash benefits, and childcare allowances). The main objectives of this MSCA Fellowship are (1) to improve existing policy measurement tools to advance our ability to recognise and analyse structural inequalities in access to family policy support, (2) to investigate gender and socio-economic inequalities in access to family policies across EU and EEA countries, and (3) to explore gender and socio-economic differences in awareness about family policy entitlements and preferences for uptake.

Keywords: family policy,gender inequality,fatherhood,child related leave policies
Priorities for Addressing Opportunities and Gaps of Industrial Biotechnology for an efficient use of funding resources (PROGRESS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: Coordination and support actions
Countries involved: Germany
Call: KET Biotechnology foresight identifying gaps and high-value opportunities for the EU industry (H2020-NMBP-CSA-2016, 2016)
Start date: 2016-08-01
End date: 2017-10-31
Duration (months): 15.0
Total project cost (EUR): 492875.0
EU funding (EUR): 492875.0
Participants: 1
Project status: CLOSED

The Progress project will support and accelerate the deployment of IB in the EU indus-try by identifying high-value opportunities for IB and proposing actions to address them successfully. The CSA will conduct a multidisciplinary approach with integration of desk re-search, statistical modelling, qualitative assessment and synthesis of data and stakeholder information and perspectives on a detailed level, in order to provide good and non-biased understanding and adequate knowledge for action. The CSA will consist of three phases: First, a comprehensive and dependable information base which allows for plausible estimations on the future of IB in the EU in the short and medium-term will be provided. It consists of an integrated analysis that considers technological, societal, political, de-mand, acceptance dimensions. Therefore, quantitative (indicators, modelling) and qua-litative information will be combined. In order to identify the R&D&I needs that are con-gruent to the European capacities and to delineate adequate actions the CSA will adopt an international value chain/ecosystem perspective and provide an in-depth analysis of the most relevant value chains. Second potential desirable, realistically achievable future paths for the various value chains for IB will be elaborated. These will eventually be combined into an integrated vision for the future of IB in Europe by engaging with the different stakeholder commun-ities. In the third phase high-value opportunities for IB and related R&D&I needs will be de-ducted and prioritized. This will provide guidance on need for action to build up and focus national/regional capacities and activities on key segments. Moreover, it will pro-vide strategic guidance for the formation of an integrated European technology base. We will address potential strategies and opportunities for specific country groups as well as beneficial framework conditions for collaboration across Europe.

Keywords: industrial biotechnology,foresight,prioritizing opportunities
SIGNALING PROPENSITY IN THE MICROENVIRONMENT OF B CELL CHRONIC LYMPHOCYTIC LEUKEMIA (LeukemiaEnviron)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Czechia
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-06-01
End date: 2024-05-31
Duration (months): 60.0
Total project cost (EUR): 1499990.0
EU funding (EUR): 1499990.0
Participants: 1
Project status: SIGNED

B cell chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults. CLL cells are characterized by their universal dependency on pro-survival and pro-proliferative signals from immune niches. To achieve this they constantly re-circulate between blood and lymph nodes, which is inhibited by novel microenvironment-targeting therapies such as “BCR inhibitors”. We aim to reveal how the malignant B cells change the propensity of their signalling pathways in response to the different microenvironments such as peripheral blood vs lymph node to obtain the proliferative signals. This is of major relevance for CLL, but also transferable to the biology of some other B cell malignancies and/or normal B cells. We analyzed the “finger print” of microenvironmental interactions in many CLL samples at various times during the disease course or during therapy. The obtained data led us to hypothesize on the mechanisms of regulation of signalling propensity of two pathways that are responsible for proliferation and survival of CLL cells, namely B Cell Receptor (BCR) signalling and signals from T-cells mediated by CD40/IL4. In aim 1 we hypothesize that CD20 is one of the key proteins involved in CLL cell activation, and influences BCR and interleukin signalling (see figure). This has important therapeutic implication since CD20 is used as a therapeutic target for 20 years (rituximab), but its function in CLL/normal B cells is unknown. In aim 2 we hypothesize that miR-29 acts a key regulator of T-cell signalling from CD40 and down-stream NFkB activation (see figure). This represents the first example of miRNAs‘ role in the propensity of T-cell interaction, and could be also utilized therapeutically. In aim 3 we will integrate our data on microenvironmental signaling (aim 1+2) and develop a first mouse model for PDX that would allow stable engraftment of primary CLL cells. Currently, CLL is non-transplantable to any animal model which complicates studies of its biology.

Keywords: chronic lymphocytic leukemia,b cells,b cell receptor signalling,microrna,mirna,therapy,microenvironment